Who We Are

MaxNova is a neurotech company. We transform significant innovations into life-changing solutions for patients with neurological disorders through an Open Innovation approach.

Problem

By 2030, China’s population aged 60 and above is expected to reach 350 million. With the aging population, China sees an increasing number of patients suffering from neurological disorders.

Solution

We adopt an Open Innovation approach in the development of neurotech products. Through partnerships, localization, and commercialization, we strive to transform the world’s cutting-edge neurotech innovations into life-changing solutions for neurological disorder patients.

Our Mission

MaxNova is committed to developing innovative neurotech solutions to improve the quality of life of patients with neurological disorders.

Why MaxNova

MaxNova was founded by a team of professionals with over 25 years’ experience in the healthcare industry who bring in a wealth of knowledge and expertise. We are based in Hong Kong, a global financial hub, which provides us with a strong foundation for sustainable capital funding for our projects and access to established market resources to support the growth and success of our business.

Deep Knowledge

MaxNova is led by a team of seasoned professionals with a wide range of experience in the medical industry. Our deep and proven healthcare expertise spreads across everything we do. This team has a shared mission: transform great innovations into life-impacting neurotech solutions. At each step, we apply substantial know-how in China’s healthcare market to minimize roadblocks and maximize efficiency.

Deep Knowledge

MaxNova is led by a team of seasoned professionals with a wide range of experience in the medical industry. Our deep and proven healthcare expertise spreads across everything we do.

This team has one shared mission: transform great innovations into life-impacting NeuroTech solutions. At each step, we apply substantial know-how in China’s healthcare market to minimize roadblocks and maximize efficiency.

Robust Funding

Promising innovations need strong backing to move forward and unleash their full potential. We work with active and involved healthcare investors to reshape our technologies from incubation into monetization. Based in a world-leading financial and capital hub, we are positioned to build a vibrant open innovation ecosystem to connect stakeholders, facilitate collaborations, and catalyze innovations.

Robust Funding

Promising innovations need strong backing to move forward and unleash their full potential. We work with active and involved healthcare investors to reshape our technologies from incubation into monetization.

Based in a world-leading financial and capital hub, we are positioned to build a vibrant open innovation ecosystem to connect stakeholders, facilitate collaborations, and catalyze innovations.

Extensive Resources

Thanks to our established network of regulatory, reimbursement, manufacturing, and commercialization platforms, we support and champion the development of promising innovations at every stage.

We combine and complement our resources with our partners to unlock the value of novel technologies and further strengthen our ability to continue investing in innovative therapies.

Extensive Resources

Thanks to our established network of regulatory, reimbursement, manufacturing, and commercialization platforms, we support and champion the development of promising innovations at every stage.

We combine and complement our resources with our partners to unlock the value of novel technologies and further strengthen our ability to continue investing in innovative therapies.

Leadership

Our core executives comprise a group of industry veterans with profound knowledge of medical technologies and extensive experience across product development. We established a global team to implement our Three-Step Solutionthat serves our mission to impact patients, communities, and healthcare positively.

Executive Management

Louis Wang

Chief Executive Officer

Olga Yanovskaya

Olga Yanovskaya

President, Global

Justin Shen

Chief Financial Officer

Hua Gu

President, USA

Kitty Li

Chief Operational Officer

Daniel Zhou

Technology Commercialization

Li Ye

Business Development, China

Young Zhang

GM, Marketing & Sales, China

Phoenix Zhou

Medical Expert

Alina Zhang

Strategic Investment, Asia

Board of Directors

Louis Wang

Chairman

Olga Yanovskaya

Director

Hua Gu

Director

Kitty Li

Director

Michael Tung

Director

Advisory Board

Alexander Wallstein

Global Operations

Mounang Desai

Healthcare Insights, USA

Jason Gu

Startup, USA

Strategic Investment

Capital Funding

Our progressive strategy of investing in NeuroTech innovations, coupled with solid expertise in building deep relationships with entrepreneurs, executives, and investors across the healthcare industry, are significant factors contributing to the success of our projects and the growth of our partners.

We work with leading venture capitalists and private equity funds specialized in healthcare in China and Asia markets to invest in today’s ideas to forge a path for better healthcare tomorrow.

Strategic Investment

Capital Funding

Our progressive strategy of investing in NeuroTech innovations, coupled with solid expertise in building deep relationships with entrepreneurs, executives, and investors across the healthcare industry, are significant factors contributing to the success of our projects and the growth of our partners.

We work with leading venture capitalists and private equity funds specialized in healthcare in China and Asia markets to invest in today’s ideas to forge a path for better healthcare tomorrow.